Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

OABI

OmniAb Inc

Feb 13 • 04:00PM ET

1.70

+0.01 0.59 %

Healthcare • Biotechnology • USA • NASD

Peers: REGN VRTX ONC EBS FOLD KURA MGNX ADAP XBIT ONCT

| Held by: VTI IWM VXF IBB IWN VTWO SCHA IWC VHT DFAS

Index	RUT	P/E	-	EPS (ttm)	-0.59	Insider Own	24.25%	Shs Outstand	143.96M	Perf Week	0.00%
Market Cap	244.72M	Forward P/E	-	EPS next Y	-0.39	Insider Trans	0.09%	Shs Float	109.04M	Perf Month	-10.99%
Enterprise Value	206.29M	PEG	-	EPS next Q	-0.09	Inst Own	44.01%	Short Float	5.35%	Perf Quarter	8.28%
Income	-63.67M	P/S	11.60	EPS this Y	11.27%	Inst Trans	5.11%	Short Ratio	11.79	Perf Half Y	-15.00%
Sales	21.09M	P/B	0.88	EPS next Y	27.69%	ROA	-19.86%	Short Interest	5.84M	Perf YTD	-8.11%
Book/sh	1.93	P/C	4.11	EPS next 5Y	23.56%	ROE	-22.37%	52W High	4.02 -57.71%	Perf Year	-53.30%
Cash/sh	0.41	P/FCF	-	EPS past 3/5Y	-22.79% -	ROIC	-21.61%	52W Low	1.22 39.34%	Perf 3Y	-55.44%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-8.76% -	Gross Margin	8.77%	Volatility	6.84% 6.39%	Perf 5Y	-
Dividend TTM	-	EV/Sales	9.78	EPS Y/Y TTM	5.16%	Oper. Margin	-321.85%	ATR (14)	0.12	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.00	Sales Y/Y TTM	3.36%	Profit Margin	-301.83%	RSI (14)	39.44	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.00	EPS Q/Q	9.94%	SMA20	-6.93%	Beta	0.16	Target Price	7.33
Payout	-	Debt/Eq	0.08	Sales Q/Q	-46.33%	SMA50	-10.77%	Rel Volume	0.72	Prev Close	1.69
Employees	114	LT Debt/Eq	0.06	Earnings	Nov 04 AMC	SMA200	-2.45%	Avg Volume	495.03K	Price	1.70
IPO	Sep 30, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-1.67% -48.98%	Trades		Volume	354,488	Change	0.59%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-29-23	Initiated	RBC Capital Mkts	Outperform	$6
Apr-21-23	Initiated	The Benchmark Company	Buy	$8
Apr-13-23	Initiated	Craig Hallum	Buy	$10
Feb-22-23	Initiated	Cowen	Outperform	$10
Feb-13-23	Initiated	H.C. Wainwright	Buy	$11
Dec-20-22	Initiated	Truist	Buy	$10
Dec-16-22	Initiated	Credit Suisse	Outperform	$13
Nov-29-22	Initiated	SVB Leerink	Outperform	$6
Nov-28-22	Initiated	Stifel	Buy	$12

Dec-15-25 04:05PM	Launch of OmniUltra Expands OmniAb's Reach into New Markets and Applications, Advances Leadership in Antibody Discovery Technologies (Business Wire) -5.58%
Dec-11-25 10:17AM	Platform Technologies Drive $211B Surge in Precision Cancer Treatment (PR Newswire) +8.00%
Dec-04-25 04:05PM	OmniAb to Hold OmniUltra Virtual Investor Event on December 15 (Business Wire)
Nov-17-25 05:23PM	OmniAb Enters into a Technology License and Services Agreement for Antibody Discovery with a Newly-Formed Incubated Company of ArrowMark Partners and Viking Global Investors (Business Wire) +5.92%
Nov-05-25 12:06AM	OmniAb Inc (OABI) Q3 2025 Earnings Call Highlights: Strong Program Momentum Amid Revenue Decline (GuruFocus.com)
06:35PM	Loading…
Nov-04-25 06:35PM	OmniAb, Inc. (OABI) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:05PM	OmniAb Reports Third Quarter 2025 Financial Results and Business Highlights (Business Wire)
Nov-03-25 08:07AM	What To Expect From OmniAb Inc (OABI) Q3 2025 Earnings (GuruFocus.com)
Oct-30-25 10:00AM	Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-28-25 10:00AM	OmniAb, Inc. (OABI) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-16-25 08:55AM	Zevra Therapeutics (ZVRA) Surges 12.3%: Is This an Indication of Further Gains? (Zacks)
08:00AM	OmniAb to Participate in Three Investor Conferences in November (Business Wire)
Oct-14-25 08:00AM	OmniAb to Report Third Quarter 2025 Financial Results on November 4 (Business Wire)
Sep-02-25 08:00AM	OmniAb to Participate at the H.C. Wainwright 27th Annual Global Investment Conference (Business Wire)
Aug-25-25 07:00AM	OmniAb Announces $30 Million Private Placement (Business Wire) -11.89%
06:15PM	Loading…
Aug-06-25 06:15PM	OmniAb, Inc. (OABI) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -5.39%
04:05PM	OmniAb Reports Second Quarter 2025 Financial Results and Business Highlights (Business Wire)
Aug-05-25 10:26AM	OmniAb Inc (OABI) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Jul-16-25 08:00AM	OmniAb to Report Second Quarter 2025 Financial Results on August 6 (Business Wire)
Jun-30-25 09:50AM	AI Is Quietly Reinventing Healthcare--And Real Deployments Are Now Underway (PR Newswire)
May-13-25 04:05PM	OmniAb Showcases Innovative High-Throughput Single B-cell Screening xPloration Platform at the 21st Annual PEGS Boston Summit (Business Wire) +8.57%
May-09-25 08:31AM	Is OmniAb, Inc. (OABI) the Low Risk High Reward Stock Set to Triple by 2030? (Insider Monkey) -8.28%
May-08-25 05:40PM	OmniAb, Inc. (OABI) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:06PM	OmniAb Reports First Quarter 2025 Financial Results and Business Highlights (Business Wire)
04:05PM	OmniAb Introduces the xPloration® Partner Access Program (Business Wire)
May-05-25 12:59PM	VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program (GlobeNewswire)
May-01-25 08:00AM	OmniAb to Participate in Five Upcoming Investor Conferences (Business Wire)
Apr-21-25 08:00AM	OmniAb Announces Two New Appointments to its Board of Directors (Business Wire)
Apr-14-25 08:00AM	OmniAb to Report First Quarter 2025 Financial Results on May 8 (Business Wire)
Mar-18-25 04:05PM	OmniAb Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights (Business Wire) -20.38%
08:00AM	Loading…
Feb-24-25 08:00AM	OmniAb to Report Fourth Quarter 2024 Financial Results on March 18 (Business Wire)
Feb-03-25 04:57PM	OmniAb to Participate in Two Investor Conferences in March (Business Wire)
Dec-16-24 04:15PM	OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering and Therapeutics Conference (Business Wire)
Nov-12-24 04:05PM	OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights (Business Wire) -9.35%
Oct-30-24 08:00AM	OmniAb to Participate in Two Investor Conferences in November (Business Wire)
Oct-22-24 08:00AM	OmniAb to Report Third Quarter 2024 Financial Results on November 12 (Business Wire)
Aug-26-24 08:00AM	OmniAb to Participate in Two Investor Conferences in September (Business Wire)
Aug-08-24 04:05PM	OmniAb Reports Second Quarter 2024 Financial Results and Business Highlights (Business Wire) +5.67%
Jul-25-24 08:00AM	OmniAb to Report Second Quarter 2024 Financial Results on August 8 (Business Wire)
Jun-03-24 04:05PM	OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of Immunology (Business Wire)
May-20-24 08:05AM	OmniAb to Participate in the Jefferies Global Healthcare Conference (Business Wire)
May-15-24 04:05PM	OmniAb Presents High-Throughput Single B-cell Screening xPloration Data at the 20th Annual PEGS Boston Summit (Business Wire)
May-12-24 03:24PM	5 Penny Stocks with Insider Buying in 2024 (Insider Monkey)
May-09-24 08:56PM	OABI Stock Earnings: OmniAb Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:05PM	OmniAb Reports First Quarter 2024 Financial Results and Business Highlights (Business Wire)
May-01-24 08:00AM	OmniAb to Participate in Five Investor Conferences in May (Business Wire)
Apr-22-24 08:00AM	OmniAb to Report First Quarter 2024 Financial Results on May 9 (Business Wire)
Mar-21-24 11:31AM	OmniAb, Inc. (NASDAQ:OABI) Q4 2023 Earnings Call Transcript (Insider Monkey) -5.17%
Mar-20-24 08:54PM	OABI Stock Earnings: OmniAb Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:05PM	OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (Business Wire)
Feb-28-24 08:27AM	OmniAb, Inc. (OABI) Soars 10.5%: Is Further Upside Left in the Stock? (Zacks)
Feb-26-24 08:00AM	OmniAb to Report Fourth Quarter 2023 Financial Results on March 20 (Business Wire)
Feb-20-24 08:00AM	OmniAb to Participate in Two Investor Conferences in March (Business Wire)
Dec-14-23 04:30PM	OmniAb Presents New Scientific Data on its OmnidAb Platform at the 2023 Antibody Engineering & Therapeutics Conference (Business Wire)
Nov-20-23 12:39PM	OmniAb, Inc. (NASDAQ:OABI) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-14-23 05:03AM	Insider Buying: OmniAb Inc CEO Matthew Foehr Acquires 95,000 Shares (GuruFocus.com) +6.32%
Nov-09-23 05:55PM	OmniAb Highlights OmnidAb Launch and its Expanding Drug Discovery Platform at Todays Research & Technology Virtual Event (Business Wire)
09:24AM	OmniAb Inc (OABI) Reports Decline in Q3 Revenue and Widening Net Loss (GuruFocus.com)
08:00AM	OmniAb Reports Third Quarter 2023 Financial Results and Business Highlights (Business Wire)
Nov-02-23 08:00AM	OmniAb to Participate in Two Investor Conferences in November (Business Wire)
Nov-01-23 09:00AM	OmniAb Appoints Steve Love to its Board of Directors (Business Wire)
Oct-31-23 04:28PM	OmniAb Announces Agenda for its Research & Technology Virtual Event (Business Wire)
Oct-26-23 02:32PM	7 of the Best Cheap Stocks to Buy Under $5 in October 2023 (InvestorPlace)
Oct-12-23 08:00AM	OmniAb to Hold Research & Technology Virtual Event on November 9 (Business Wire)
Sep-05-23 08:00AM	OmniAb to Participate in Two Investor Conferences in September (Business Wire)
Aug-15-23 05:20AM	OmniAb, Inc. (NASDAQ:OABI) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-13-23 08:06AM	OmniAb, Inc. (NASDAQ:OABI) Analysts Are Cutting Their Estimates: Here's What You Need To Know (Simply Wall St.)
Aug-10-23 04:05PM	OmniAb Reports Second Quarter 2023 Financial Results and Business Highlights (Business Wire) -5.54%
Aug-07-23 04:05PM	OmniAb Announces the Passing of Director Sunil Patel (Business Wire)
Jul-31-23 08:00AM	OmniAb to Report Second Quarter 2023 Financial Results on August 10 (Business Wire)
Jul-17-23 07:35AM	With 60% institutional ownership, OmniAb, Inc. (NASDAQ:OABI) is a favorite amongst the big guns (Simply Wall St.)
Jun-13-23 06:00AM	7 Stocks to Buy for 200% Returns This Year (InvestorPlace) +6.32%
May-18-23 05:09PM	7 Stocks to Buy for Their Massive Upside Potential (InvestorPlace)
May-17-23 04:05PM	OmniAb Launches OmniDeep at the PEGS Boston Conference and Expo (Business Wire)
May-16-23 06:06AM	President of OmniAb Matthew Foehr Buys 22% More Shares \ (Simply Wall St.) +9.12%
May-14-23 08:03AM	OmniAb, Inc. (NASDAQ:OABI) Analysts Just Cut Their EPS Forecasts Substantially (Simply Wall St.)
May-11-23 10:55PM	Q1 2023 OmniAb Inc Earnings Call (Thomson Reuters StreetEvents) +8.36%
07:00AM	OmniAb Reports First Quarter 2023 Financial Results and Business Highlights (Business Wire)
May-05-23 07:14AM	OmniAb, Inc.'s (NASDAQ:OABI) Share Price Matching Investor Opinion (Simply Wall St.)
May-04-23 06:26AM	10 Best Small-Cap Growth Stocks to Buy Now (Insider Monkey)
May-01-23 08:00AM	OmniAb to Report First Quarter 2023 Financial Results on May 11 (Business Wire)
Apr-26-23 08:01PM	7 Biotech Stocks With Huge Return Potential for Long-Term Investors (InvestorPlace)
Apr-25-23 08:00AM	OmniAb to Participate in Upcoming Investor Conferences in May (Business Wire)
Apr-19-23 08:30AM	Here's How Much a $1000 Investment in Ligand Pharmaceuticals Made 10 Years Ago Would Be Worth Today (Zacks)
Apr-07-23 10:24PM	OmniAb, Inc. (NASDAQ:OABI) Q4 2022 Earnings Call Transcript (Insider Monkey)
Apr-05-23 06:09AM	OmniAb Full Year 2022 Earnings: Beats Expectations (Simply Wall St.)
Apr-02-23 08:51AM	Insiders of OmniAb, Inc. (NASDAQ:OABI) are up 11% on their US$2.3m purchase after OmniAb, Inc. (NASDAQ:OABI) rose 14% last week (Simply Wall St.)
Mar-31-23 08:40AM	Do Options Traders Know Something About OmniAb (OABI) Stock We Don't? (Zacks)
Mar-30-23 04:05PM	OmniAb Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights (Business Wire)
Mar-15-23 11:44AM	7 Biotech Stocks That Could Be the Next Big Thing (InvestorPlace)
Mar-09-23 08:00AM	OmniAb to Report Fourth Quarter 2022 Financial Results on March 30 (Business Wire) -5.03%
Mar-08-23 09:53AM	These 2 Strong Buy Penny Stocks Are Poised for a Massive Rally, Say Analysts (TipRanks)
Feb-23-23 07:49AM	Ligand's (LGND) Q4 Sales & Earnings Top, View Raised, Stock Up (Zacks)
Feb-07-23 08:00AM	OmniAb to Participate in Three Upcoming Investor Conferences (Business Wire)
Feb-01-23 06:56AM	With 44% stake, OmniAb, Inc. (NASDAQ:OABI) seems to have captured institutional investors' interest (Simply Wall St.)
Dec-16-22 12:39PM	Some 'Transgenic Animal Platforms Are More Than Equal,' Analyst Initiating Coverage On OmniAb Says (Benzinga)
Dec-01-22 08:47AM	Hillstream BioPharma Announces Development of Proprietary Targeted Biologics, Knob Quatrabodies (HSB-1940) against PD-1, by combining Quatramers with OmniAbs Picobodies, via a Collaboration Agreement, against Novel, Unreachable and Undruggable Epitopes in High Value Validated Targets (GlobeNewswire) -5.37%
Nov-15-22 07:00AM	OmniAb Reports Third Quarter 2022 Financial Results and Business Highlights (Business Wire) -10.00%
Nov-03-22 08:00AM	OmniAb to Participate in Two Upcoming Investor Conferences (Business Wire)
Nov-02-22 07:00AM	OmniAb, Inc. to Ring Nasdaq Stock Market Opening Bell (Business Wire) -60.65%

OmniAb, Inc. operates as a drug discovery company. It focuses on developing human monoclonal and bispecific therapeutic antibodies. Its platform includes the biological intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse. The company was founded on December 14, 2015 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Berkman Charles S	Chief Legal Officer	Dec 07 '25	Option Exercise	0.00	15,621	0	385,115	Dec 09 09:02 AM
Berkman Charles S	Chief Legal Officer	Dec 08 '25	Sale	1.96	8,044	15,766	377,071	Dec 09 09:02 AM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Dec 07 '25	Option Exercise	0.00	46,500	0	276,610	Dec 09 09:02 AM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Dec 08 '25	Sale	1.96	23,922	46,887	252,688	Dec 09 09:02 AM
FOEHR MATTHEW W	President and CEO	Dec 07 '25	Option Exercise	0.00	26,554	0	4,373,749	Dec 09 09:01 AM
FOEHR MATTHEW W	President and CEO	Dec 08 '25	Sale	1.96	13,666	26,785	4,360,083	Dec 09 09:01 AM
GUSTAFSON KURT A	Officer	Dec 08 '25	Proposed Sale	1.96	23,922	46,910		Dec 08 07:17 PM
FOEHR MATTHEW W	Officer	Dec 08 '25	Proposed Sale	1.96	13,666	26,798		Dec 08 07:15 PM
Berkman Charles S	Officer	Dec 08 '25	Proposed Sale	1.96	8,044	15,774		Dec 08 07:14 PM
HIGGINS JOHN L	Director	Nov 07 '25	Buy	1.38	41,038	56,632	2,929,148	Nov 10 08:30 AM
HIGGINS JOHN L	Director	Nov 06 '25	Buy	1.41	36,223	51,074	2,888,110	Nov 10 08:30 AM
Cochran Jennifer R.	Director	May 15 '25	Buy	1.52	30,000	45,600	145,274	May 15 04:02 PM
Love Steven	Director	May 14 '25	Buy	1.46	25,000	36,500	38,333	May 14 05:04 PM
HIGGINS JOHN L	Director	May 12 '25	Buy	1.44	65,000	93,600	2,831,887	May 13 05:52 PM
FOEHR MATTHEW W	President and CEO	Apr 07 '25	Option Exercise	0.00	36,458	0	3,815,618	Apr 07 08:17 PM
FOEHR MATTHEW W	President and CEO	Apr 07 '25	Sale	2.00	19,382	38,764	3,796,236	Apr 07 08:17 PM
Berkman Charles S	Chief Legal Officer	Apr 07 '25	Option Exercise	0.00	13,542	0	370,418	Apr 07 08:10 PM
Berkman Charles S	Chief Legal Officer	Apr 07 '25	Sale	2.00	7,206	14,412	363,212	Apr 07 08:10 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Apr 07 '25	Option Exercise	0.00	13,542	0	231,034	Apr 07 08:09 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Apr 07 '25	Sale	2.00	7,206	14,412	223,828	Apr 07 08:09 PM
GUSTAFSON KURT A	Officer	Apr 07 '25	Proposed Sale	2.00	7,206	14,396		Apr 07 08:04 PM
FOEHR MATTHEW W	Officer	Apr 07 '25	Proposed Sale	2.00	19,382	38,715		Apr 07 08:00 PM
Berkman Charles S	Officer	Apr 07 '25	Proposed Sale	2.00	7,206	14,396		Apr 07 07:56 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Apr 01 '25	Option Exercise	0.00	23,244	0	229,455	Apr 01 08:43 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Apr 01 '25	Sale	2.37	11,963	28,352	217,492	Apr 01 08:43 PM
GUSTAFSON KURT A	Officer	Apr 01 '25	Proposed Sale	2.37	11,963	28,351		Apr 01 07:16 PM
HIGGINS JOHN L	Director	Mar 21 '25	Buy	2.28	4,000	9,120	2,766,887	Mar 21 07:58 PM
HIGGINS JOHN L	Director	Mar 20 '25	Buy	2.35	125,750	295,512	2,762,887	Mar 20 08:15 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Feb 16 '25	Option Exercise	0.00	13,541	0	213,466	Feb 19 08:51 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Feb 19 '25	Sale	3.67	7,255	26,626	206,211	Feb 19 08:51 PM
FOEHR MATTHEW W	President and CEO	Feb 19 '25	Sale	3.67	19,522	71,646	3,779,160	Feb 19 08:51 PM
FOEHR MATTHEW W	President and CEO	Feb 18 '25	Sale	3.68	13,964	51,388	3,798,682	Feb 19 08:51 PM
Berkman Charles S	Chief Legal Officer	Feb 18 '25	Sale	3.68	8,215	30,231	364,131	Feb 19 08:50 PM
Berkman Charles S	Chief Legal Officer	Feb 19 '25	Sale	3.67	7,255	26,626	356,876	Feb 19 08:50 PM
GUSTAFSON KURT A	Officer	Feb 19 '25	Proposed Sale	3.68	5,188	19,092		Feb 18 08:36 PM
FOEHR MATTHEW W	Officer	Feb 18 '25	Proposed Sale	3.68	13,964	51,390		Feb 18 08:30 PM
Berkman Charles S	Officer	Feb 18 '25	Proposed Sale	3.68	8,215	30,232		Feb 18 08:28 PM

Open in Screener

TECH

Bio-Techne Corp

Feb 13 • 04:00PM ET

59.93

+0.39 0.66 %

Healthcare • Biotechnology • USA • NASD

Peers: TMO DHR ILMN A BIO QGEN NEO MTD

| Held by: VTI VOO VB RSP IVV VBK SPY FBT XLV IBB

Index	S&P 500	P/E	116.57	EPS (ttm)	0.51	Insider Own	1.21%	Shs Outstand	155.88M	Perf Week	-10.26%
Market Cap	9.38B	Forward P/E	27.44	EPS next Y	2.18	Insider Trans	-1.77%	Shs Float	154.56M	Perf Month	-12.38%
Enterprise Value	9.55B	PEG	2.90	EPS next Q	0.54	Inst Own	109.04%	Short Float	6.37%	Perf Quarter	-2.39%
Income	81.07M	P/S	7.71	EPS this Y	3.49%	Inst Trans	3.54%	Short Ratio	4.78	Perf Half Y	11.52%
Sales	1.22B	P/B	4.65	EPS next Y	9.91%	ROA	3.12%	Short Interest	9.84M	Perf YTD	1.90%
Book/sh	12.90	P/C	54.24	EPS next 5Y	9.47%	ROE	3.96%	52W High	72.16 -16.95%	Perf Year	-10.24%
Cash/sh	1.10	P/FCF	42.04	EPS past 3/5Y	-34.80% -20.58%	ROIC	3.45%	52W Low	46.01 30.25%	Perf 3Y	-22.26%
Dividend Est.	0.32 (0.53%)	EV/EBITDA	25.25	Sales past 3/5Y	3.33% 10.55%	Gross Margin	66.57%	Volatility	4.12% 4.22%	Perf 5Y	-39.90%
Dividend TTM	0.32 (0.53%)	EV/Sales	7.86	EPS Y/Y TTM	-48.18%	Oper. Margin	22.60%	ATR (14)	2.70	Perf 10Y	183.42%
Dividend Ex-Date	Feb 13, 2026	Quick Ratio	3.08	Sales Y/Y TTM	1.64%	Profit Margin	6.67%	RSI (14)	37.50	Recom	1.79
Dividend Gr. 3/5Y	0.00% 0.00%	Current Ratio	4.54	EPS Q/Q	11.46%	SMA20	-9.29%	Beta	1.48	Target Price	75.25
Payout	69.67%	Debt/Eq	0.17	Sales Q/Q	-0.39%	SMA50	-5.35%	Rel Volume	1.79	Prev Close	59.54
Employees	3100	LT Debt/Eq	0.17	Earnings	Feb 04 BMO	SMA200	5.32%	Avg Volume	2.06M	Price	59.93
IPO	Feb 09, 1989	Option/Short	Yes / Yes	EPS/Sales Surpr.	5.99% 1.86%	Trades		Volume	3,679,165	Change	0.66%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-03-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$73
Aug-21-25	Upgrade	Citigroup	Neutral → Buy	$70
Jul-22-25	Resumed	Stephens	Overweight	$65
Jul-09-25	Initiated	TD Cowen	Buy	$65
May-30-25	Initiated	Wells Fargo	Overweight	$59
Apr-09-25	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Mar-18-25	Initiated	Evercore ISI	Outperform	$75
Feb-19-25	Downgrade	Robert W. Baird	Outperform → Neutral	$88 → $68
May-22-24	Downgrade	Citigroup	Buy → Neutral	$85
Feb-08-24	Initiated	Scotiabank	Sector Outperform	$80
Feb-02-24	Downgrade	Stifel	Buy → Hold	$65
Dec-07-23	Initiated	UBS	Buy	$80
Aug-28-23	Initiated	William Blair	Outperform
Jan-10-23	Upgrade	Wells Fargo	Underweight → Equal Weight	$90
Dec-14-22	Initiated	Deutsche Bank	Buy	$100
Dec-12-22	Upgrade	Citigroup	Neutral → Buy	$81.25 → $100
Dec-07-22	Initiated	RBC Capital Mkts	Sector Perform	$89
Aug-25-22	Initiated	Credit Suisse	Outperform	$465
Apr-25-22	Downgrade	Wells Fargo	Equal Weight → Underweight	$370
Sep-15-21	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight	$600

Show Previous Ratings

Today 10:32AM	Analyst Report: Bio-Techne Corporation (Morningstar Research)
Feb-11-26 12:04PM	What Are Wall Street Analysts' Target Price for Bio-Techne Stock? (Barchart)
09:00AM	Bio-Techne Announces Changes to its Leadership Team (PR Newswire)
12:36AM	5 Insightful Analyst Questions From Bio-Techne's Q4 Earnings Call (StockStory)
Feb-06-26 10:22AM	Analyst Report: Bio-Techne Corporation (Morningstar Research)
12:34AM	Loading…
Feb-05-26 12:34AM	TECH Q4 Deep Dive: Margin Expansion and Flat Revenue Amid Mixed End Markets (StockStory)
Feb-04-26 04:01PM	Bio-Techne Corp (TECH) Q2 2026 Earnings Call Highlights: Strategic Growth and Margin Expansion ... (GuruFocus.com) +6.25%
11:22AM	Bio-Techne Q2 Earnings Call Highlights (MarketBeat)
10:38AM	Bio-Techne (TECH) Q2 2026 Earnings Call Transcript (Motley Fool)
09:34AM	TECH Q2 Earnings & Revenues Beat Estimates, Operating Margin Up (Zacks)
09:30AM	Techne (TECH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
07:40AM	Techne (TECH) Beats Q2 Earnings and Revenue Estimates (Zacks)
06:37AM	Bio-Techne (NASDAQ:TECH) Surprises With Q4 CY2025 Sales (StockStory)
06:30AM	Bio-Techne Releases Second Quarter Fiscal 2026 Results (PR Newswire)
06:30AM	Bio-Techne Declares Dividend (PR Newswire)
08:29AM	Loading…
Feb-03-26 08:29AM	MedTech Stocks to Watch for Earnings on Feb. 4: BSX, ALGN & More (Zacks)
Feb-02-26 10:04PM	Bio-Techne (TECH) Reports Earnings Tomorrow: What To Expect (StockStory)
06:30AM	Bio-Techne Expands 3D Stem Cell and Organoid Culture Portfolio with a Fully Defined Synthetic Alternative (PR Newswire)
Jan-30-26 11:40AM	CSLLY or TECH: Which Is the Better Value Stock Right Now? (Zacks)
08:44AM	Bio-Techne's Q2 Earnings on Deck: What's in Store for the Stock? (Zacks)
Jan-28-26 06:30AM	Bio-Techne Launches Simple Plex Ultra-Sensitive Assays on Ella Platform to Enable Femtogram-Level Detection of Neurological Biomarkers (PR Newswire)
Jan-20-26 07:00AM	Bio-Techne to Host Conference Call on February 4, 2026, to Announce Second Quarter Fiscal 2026 Financial Results (PR Newswire)
Jan-12-26 06:49PM	Analyst Report: Bio-Techne Corporation (Morningstar Research)
Jan-09-26 08:37AM	Here's What to Expect From Bio-Techne's Next Earnings Report (Barchart)
Jan-05-26 11:05PM	3 Reasons to Avoid TECH and 1 Stock to Buy Instead (StockStory) +5.67%
Jan-03-26 07:20AM	Klaviyo, Wingstop among Stephens Best Ideas for 2026 (TipRanks)
Dec-30-25 10:34PM	Research Tools & Consumables Stocks Q3 Results: Benchmarking Bio-Techne (NASDAQ:TECH) (StockStory)
Dec-23-25 07:00AM	Bio-Techne to Present at the 2026 J.P. Morgan Healthcare Conference (PR Newswire)
Dec-22-25 09:17AM	Enanta Pharmaceuticals (ENTA) Surges 5.9%: Is This an Indication of Further Gains? (Zacks)
Dec-16-25 07:40AM	Bio-Techne Stock: Is TECH Underperforming the Healthcare Sector? (Barchart)
09:36AM	Loading…
Dec-11-25 09:36AM	Here's Why BioTechne (TECH) Traded Lower in Q3 (Insider Monkey)
06:30AM	Bio-Techne Partners with the Wyss Center Geneva to Advance Automated 3D Multiomics Technology and Accelerate Spatial Biology (PR Newswire)
Dec-09-25 06:30AM	Bio-Techne Launches the Enhanced Leo System Delivering Advanced Multiplexing and High-Throughput Protein Analysis (PR Newswire)
Dec-04-25 10:29AM	Bio-Techne Corporation (TECH): A Bull Case Theory (Insider Monkey)
Nov-25-25 07:00AM	Bio-Techne to Present at Upcoming Investor Conferences (PR Newswire)
Nov-18-25 06:30AM	Bio-Techne Licenses AI-Designed NovoBody Duo Molecules from Monod Bio to Expand Recombinant Protein Portfolio (PR Newswire)
Nov-13-25 11:28PM	Bio-Techne Stock: Is Wall Street Bullish or Bearish? (Barchart)
09:01AM	Is Bio-Techne Corporation (TECH) a High-Quality Growth-Oriented Compounder Within The Healthcare Sector? (Insider Monkey)
Nov-11-25 03:55PM	Bio-Techne, Tandem Diabetes, Align Technology, DexCom, and Teleflex Shares Skyrocket, What You Need To Know (StockStory)
Nov-07-25 05:36PM	McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. (Barrons.com)
Nov-06-25 07:00AM	Bio-Techne to Present at Upcoming Investor Conferences (PR Newswire)
Nov-05-25 09:57PM	Analyst Report: Bio-Techne Corporation (Morningstar Research)
04:03PM	Bio-Techne Corp (TECH) Q1 2026 Earnings Call Highlights: Navigating Challenges with Strategic ... (GuruFocus.com)
10:52AM	TECH Stock Falls on Q1 Earnings Meet, Revenues Miss, Margins Up (Zacks)
09:30AM	Here's What Key Metrics Tell Us About Techne (TECH) Q1 Earnings (Zacks)
07:40AM	Techne (TECH) Meets Q1 Earnings Estimates (Zacks)
06:38AM	Bio-Techne (NASDAQ:TECH) Misses Q3 Revenue Estimates, Stock Drops (StockStory)
06:30AM	Bio-Techne Releases First Quarter Fiscal 2026 Results (PR Newswire)
06:30AM	BIO-TECHNE DECLARES DIVIDEND (PR Newswire)
Nov-04-25 09:01AM	AI-Powered Spatial Biology Workflow from Bio-Techne and Nucleai Enables Predictive Biomarker Discovery in Melanoma Patients (PR Newswire)
Nov-03-25 10:17PM	What To Expect From Bio-Techne's (TECH) Q3 Earnings (StockStory)
07:00AM	ScaleReady Announces a G-Rex Grant has been awarded to Sonoma Biotherapeutics (PR Newswire)
Oct-31-25 03:21PM	Why Bio-Techne (TECH) Stock Is Up Today (StockStory)
Oct-30-25 07:27PM	Analyst Report: Bio-Techne Corporation (Morningstar Research)
Oct-29-25 10:00AM	Techne (TECH) Reports Next Week: What to Know Ahead of the Release (Zacks)
Oct-28-25 06:30AM	Bio-Techne Launches ProximityScope Assay on the BOND RX platform from Leica Biosystems to Advance Spatial Protein-Protein Interactions Research (PR Newswire)
Oct-23-25 06:56PM	Analyst Report: Bio-Techne Corporation (Morningstar Research)
07:54AM	Bio-Techne Q1 Earnings Preview: What's in Store for the Stock? (Zacks)
07:00AM	ScaleReady Announces multiple G-Rex Grants have been awarded to leading investigators at Children's National Hospital (PR Newswire)
Oct-16-25 12:04AM	3 Reasons to Avoid TECH and 1 Stock to Buy Instead (StockStory)
Oct-15-25 09:00AM	Saguaro Biosciences Partners with Bio-Techne to Distribute Innovative Live-Cell Imaging Reagents (Business Wire)
07:00AM	Bio-Techne to Host Conference Call on November 5, 2025, to Announce First Quarter Fiscal 2026 Financial Results (PR Newswire)
Oct-14-25 11:40AM	GMAB or TECH: Which Is the Better Value Stock Right Now? (Zacks)
08:48AM	Earnings Preview: What to Expect From Bio-Techne's Report (Barchart)
Oct-09-25 07:00AM	Bio-Techne and Oxford Nanopore Technologies Expand Agreement to Accelerate Development of Genetics Portfolio Through 2032 (PR Newswire)
Oct-08-25 08:18AM	Should You Continue to Hold Bio-Techne Stock in Your Portfolio? (Zacks)
Oct-03-25 04:16PM	S&P 500 Stocks: These 5 Lead As Index Hits Record High (Investor's Business Daily)
Sep-30-25 04:00PM	Bio-Techne (TECH) Shares Skyrocket, What You Need To Know (StockStory) +6.51% +7.71%
Sep-29-25 08:22AM	Bio-Techne Stock Climbs on Advances in Spatial Biology Solutions (Zacks)
Sep-26-25 06:30AM	Bio-Techne Advances Spatial Biology Solutions Bridging Translational Research to Clinical Applications (PR Newswire)
Sep-24-25 07:28AM	BioTechne (TECH) Fell Over the Industry's Uncertain Funding Environment (Insider Monkey)
07:15AM	Is Bio-Techne Stock Underperforming the Dow? (Barchart)
06:59AM	Bio-Techne Highlights Progress on Climate, Innovation, and Culture in 2025 Sustainability Report (PR Newswire)
Sep-19-25 09:31AM	Strength Seen in Amicus Therapeutics (FOLD): Can Its 6.4% Jump Turn into More Strength? (Zacks)
Sep-16-25 11:31PM	Research Tools & Consumables Stocks Q2 Highlights: Bio-Techne (NASDAQ:TECH) (StockStory)
Sep-15-25 09:28AM	Here's Why The Brown Capital Small Company Fund is Re-Evaluating Bio-Techne's (TECH) Long-Term Growth Profile (Insider Monkey)
Sep-10-25 03:11PM	Why Bio-Techne (TECH) Stock Is Down Today (StockStory) -5.98%
Sep-09-25 04:05PM	CONMED Corporation Adds Kim Kelderman to its Board of Directors (Business Wire)
07:00AM	ScaleReady Awards G-Rex Grants to Support Cell and Gene Therapy Manufacturing in California (PR Newswire)
Sep-02-25 02:26PM	Why Bio-Techne (TECH) Shares Are Sliding Today (StockStory)
Aug-27-25 07:00AM	Bio-Techne to Present at Upcoming Investor Conferences (PR Newswire)
Aug-22-25 03:40PM	Bio-Techne, 10x Genomics, Lumen, EPAM, and ASGN Shares Are Soaring, What You Need To Know (StockStory) +5.72%
Aug-21-25 09:36AM	CoreWeave upgraded, Instacart downgraded: Wall Street's top analyst calls (The Fly)
Aug-19-25 07:57AM	Bio-Techne Stock: Analyst Estimates & Ratings (Barchart)
Aug-14-25 07:00AM	ScaleReady Announces Award of a G-Rex Grant to the Gates Institute's Translational Sciences Laboratory (PR Newswire)
Aug-13-25 01:35AM	The 5 Most Interesting Analyst Questions From Bio-Techne's Q2 Earnings Call (StockStory)
Aug-12-25 03:17AM	TECH Q2 Deep Dive: Margin Pressures and Portfolio Shifts Amid Market Uncertainty (StockStory) +5.34%
Aug-11-25 02:56PM	Analyst Report: Bio-Techne Corporation (Morningstar Research)
Aug-06-25 01:20PM	Why Bio-Techne (TECH) Shares Are Plunging Today (StockStory) -8.73%
09:31AM	Bio-Techne (NASDAQ:TECH) Exceeds Q2 Expectations (StockStory)
09:30AM	Here's What Key Metrics Tell Us About Techne (TECH) Q4 Earnings (Zacks)
09:05AM	Bio-Techne Q4 Earnings Beat Estimates, Gross Margin Down, Stock Falls (Zacks)
07:50AM	Techne (TECH) Beats Q4 Earnings and Revenue Estimates (Zacks)
06:30AM	Bio-Techne Releases Fourth Quarter Fiscal 2025 Results (PR Newswire)
06:30AM	BIO-TECHNE DECLARES DIVIDEND (PR Newswire)
Aug-05-25 04:30PM	Bio-Techne Announces Exosome Diagnostics Divestiture (PR Newswire)
07:00AM	ScaleReady Announces a G-Rex Grant has been awarded to Sidra Medicine (PR Newswire)
Aug-04-25 11:19PM	Earnings To Watch: Bio-Techne (TECH) Reports Q2 Results Tomorrow (StockStory)
09:51AM	Bio-Techne Q4 Earnings Preview: What's in Store for the Stock? (Zacks)
Aug-01-25 08:13AM	Bio-Techne Corporation (TECH) Slid on Weakness in Research Spending (Insider Monkey)

Bio-Techne Corp. is a global life sciences company providing innovative tools and bioactive reagents for research and clinical diagnostic communities. Its products assist scientific investigations into biological processes and the nature and progress of specific diseases. It operates through the Protein Sciences, and Diagnostics and Spatial Biology segments. The Protein Sciences segment develops and manufactures purified proteins, and reagent solutions. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products. The company was founded in 1976 and is headquartered in Minneapolis, MN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Herr Amy E.	Director	Feb 03 '26	Option Exercise	0.00	38	0	2,192	Feb 05 06:30 PM
McManus Matthew	President - Diag & Spatial Bio	Feb 01 '26	Option Exercise	0.00	4,621	0	9,356	Feb 03 05:04 PM
Hippel James	CFO	Nov 03 '25	Option Exercise	0.00	24,704	0	154,587	Nov 05 04:46 PM
Geist William	PRESIDENT, PROTEIN SCIENCES	Nov 03 '25	Option Exercise	0.00	9,911	0	25,023	Nov 05 04:46 PM
Nusse Roeland	Director	Aug 25 '25	Option Exercise	21.84	17,040	372,154	61,599	Aug 27 04:10 PM
Nusse Roeland	Director	Aug 25 '25	Sale	56.36	17,040	960,388	44,559	Aug 27 04:10 PM
BAUMGARTNER ROBERT V	Director	Aug 25 '25	Option Exercise	21.84	17,040	372,154	61,903	Aug 27 04:09 PM
BAUMGARTNER ROBERT V	Director	Aug 25 '25	Sale	56.21	17,040	957,818	44,863	Aug 27 04:09 PM
ROELAND NUSSE	Director	Aug 25 '25	Proposed Sale	56.36	17,040	960,388		Aug 25 04:05 PM
ROBERT V. BAUMGARTNER4731 BONI	Director	Aug 25 '25	Proposed Sale	56.21	17,040	957,849		Aug 25 04:04 PM
Hippel James	CFO	Aug 15 '25	Option Exercise	0.00	4,010	0	131,809	Aug 19 05:38 PM
Herr Amy E.	Director	Aug 15 '25	Option Exercise	0.00	279	0	2,255	Aug 19 05:29 PM
Kelderman Kim	Chief Executive Officer	Aug 15 '25	Option Exercise	0.00	8,543	0	55,273	Aug 19 05:28 PM
Bohnen Shane	SVP - General Counsel	Aug 15 '25	Option Exercise	0.00	1,718	0	4,912	Aug 19 05:28 PM
McManus Matthew	President - Diag & Spatial Bio	Aug 15 '25	Option Exercise	0.00	2,637	0	5,615	Aug 19 05:28 PM
Geist William	PRESIDENT, PROTEIN SCIENCES	Aug 15 '25	Option Exercise	0.00	2,623	0	15,915	Aug 19 05:27 PM
HIGGINS JOHN L	Director	Aug 07 '25	Option Exercise	21.84	5,040	110,074	65,236	Aug 11 07:06 PM
Hippel James	CFO	Jul 29 '25	Option Exercise	44.33	168,620	7,474,925	275,230	Jul 31 04:28 PM
Kelderman Kim	Chief Executive Officer	Jul 22 '25	Option Exercise	44.33	48,176	2,135,642	90,379	Jul 24 04:26 PM
Kelderman Kim	Chief Executive Officer	Jul 15 '25	Option Exercise	44.33	36,132	1,601,732	75,136	Jul 17 05:04 PM
Herr Amy E.	Director	Jun 09 '25	Option Exercise	44.33	1,280	56,742	3,256	Jun 11 04:20 PM
Herr Amy E.	Director	Jun 09 '25	Sale	49.77	1,280	63,705	1,976	Jun 11 04:20 PM
JOSHUA MOLHO	Officer	Jun 09 '25	Proposed Sale	49.77	1,280	63,705		Jun 09 04:19 PM
HIGGINS JOHN L	Director	May 01 '25	Option Exercise	21.84	12,000	262,080	60,196	May 05 04:18 PM
Bohnen Shane	SVP - General Counsel	Apr 03 '25	Option Exercise	0.00	2,260	0	3,941	Apr 07 04:25 PM
Herr Amy E.	Director	Feb 14 '25	Option Exercise	44.33	1,976	87,596	3,836	Feb 18 04:49 PM
Herr Amy E.	Director	Feb 14 '25	Sale	65.96	1,860	122,691	1,976	Feb 18 04:49 PM
JOSHUA MOLHO	Domestic Partner of Director	Feb 14 '25	Proposed Sale	65.96	1,860	122,691		Feb 14 04:08 PM

OABI

OmniAb Inc

TECH

Bio-Techne Corp

Upgrade your FINVIZ experience